Sanofi-Aventis (NASDAQ:SNY) will close 8 of its 27 R&D sites and look to build partnerships...
Sanofi-Aventis (NASDAQ:SNY) will close 8 of its 27 R&D sites and look to build partnerships with outside biotech and academic labs. The move follows an industry trend of cutting costs by relying on outside labs to discover new drugs.